A Time-Resolved FRET Activity Assay to Distinguish Enzymatic Inhibition from PROTAC-Mediated Degradation of SARS-CoV-2 Mpro.
Proteolysis-targeting chimeras (PROTACs) are emerging as a promising strategy for antiviral drug development and are mechanistically distinct from classical small-molecule inhibitors. Many PROTAC designs targeting viral proteases, such as the SARS-CoV-2 main protease (Mpro), employ warheads derived from active-site inh...